Morbimortality consequences of use and misuse of psychoactive medicines in Portugal
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70171 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Ana Carmona Araújo und 5 weiteren Autor:innen. Beteiligte Einrichtung: iMed.ULisboa - Research Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal. Hauptthemen laut MEDLINE: Psychotropic Drugs, Prescription Drug Misuse, Substance-Related Disorders. Die Arbeit nennt 73 Literaturangaben.
Abstract (Originalsprache)
Aims
To characterize the morbidity and mortality consequences of psychoactive medicines use and misuse in Portugal.
Methods
Retrospective multisource database study to estimate the risk of psychoactive medicine‐related deaths, emergency department admissions, serious poisoning calls and serious adverse drug reaction reports, including combination with alcohol and illicit drugs.
Results
Most intentional exposures to psychoactive medicines involving combinations ( n = 5973; 70.2%), antidepressants ( n = 5441; 67.1%) or any prescription opioid ( n = 355; 67.4%) resulted in serious poisonings (i.e., medical assistance advised). The risk of serious poisoning was higher for exposures involving substance combinations (relative risk [RR] = 1.12; confidence interval [95% CI): 1.10–1.14), antidepressants (RR = 1.04; 95% CI: 1.02–1.05) and alcohol and/or illicit drugs (RR = 1.18; 95% CI: 1.15–1.21). Among 6737 psychoactive medicine‐related deaths, 166 (2.5%) were identified where the medicine contributed to the fatal outcome. The risk of contribution to death was higher in cases involving substance combinations (RR = 9.03; 95% CI: 3.71–21.94), antidepressants (RR = 3.20; 95% CI: 2.28–4.49), and alcohol and/or illicit drugs (RR = 1.88; 95% CI: 1.36–2.61). Emergency department admission caused by misuse of a psychoactive medicine ( n = 5826) were more likely to involve benzodiazepines/z‐drugs (RR = 2.40; 95% CI: 2.30–2.51) or antidepressants (RR = 1.86; 95% CI: 1.80–1.93).
Conclusions
Psychoactive medicine misuse in Portugal frequently occurs alongside polysubstance use and is associated with substantial health risks. Public health strategies should prioritize addressing high‐risk medicine combinations and therapeutic groups most often found to trigger negative outcomes. This may be achieved by targeted prevention efforts integrated into health system design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- iMed.ULisboa - Research Institute for Medicines, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
- Healthcare Data, Data Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands.
- Centre for Health Evaluation & Research/Infosaúde-National Association of Pharmacies (CEFAR/IS-ANF), Lisbon, Portugal.
- Independent expert, Lisbon, Portugal.
- ICAD - Institute on Addictive Behaviours and Dependencies, P.I., Lisbon, Portugal.
ORCID-Profile: Ana Carmona Araújo, Ana Paula Martins, Filipa Alves da Costa, João Goulão
Zitieren
APA
Carmona Araújo, A., Guerreiro, J. P., Bulhosa, C., Martins, A. P., Alves da Costa, F., & Goulão, J. (2025). Morbimortality consequences of use and misuse of psychoactive medicines in Portugal. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70171
Vancouver
Carmona Araújo A, Guerreiro JP, Bulhosa C, Martins AP, Alves da Costa F, Goulão J. Morbimortality consequences of use and misuse of psychoactive medicines in Portugal. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70171
BibTeX
@article{CarmonaArajo2025,
author = {Carmona Araújo, Ana and Guerreiro, Jose Pedro and Bulhosa, Carolina and Martins, Ana Paula and Alves da Costa, Filipa and Goulão, João},
title = {Morbimortality consequences of use and misuse of psychoactive medicines in Portugal},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70171}
}
EUVIMED